![](/wp-content/uploads/2018/10/M7X28eZBSeBWlC3tAi9i.png)
$599
Biocon CY Q4 ’17 (FY Q3 ’18) Earnings Update
Biocon hosted its CY Q4 ’17 (FY Q3 ’18) earnings call and provided updates on its insulin portfolio including bs-glargine regulatory status, bs-aspart Ph1 initiation, and Tregopil (oral insulin) Ph2/3 initiation in India. Below are highlights from the call.